• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳腺癌组织胞质提取物中尿激酶型纤溶酶原激活剂(uPA)的酶联免疫吸附测定。

Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.

作者信息

Rosenquist C, Thorpe S M, Danø K, Grøndahl-Hansen J

机构信息

Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.

出版信息

Breast Cancer Res Treat. 1993 Dec;28(3):223-9. doi: 10.1007/BF00666583.

DOI:10.1007/BF00666583
PMID:8018952
Abstract

The enzyme urokinase-type plasminogen activator (uPA) plays a role in cancer invasion, and high levels of uPA in detergent extracts of mammary cancer tissue have been reported to be associated with a poor prognosis. We have explored the possibility of using mammary cancer cytosol extracts routinely prepared for steroid receptor analysis for retrospective prognostic studies of uPA. A sandwich enzyme-linked immunosorbent assay (ELISA) for uPA was developed, using polyclonal catching antibodies and a mixture of three biotinylated monoclonal detecting antibodies, that were selected to recognize free uPA, inhibitor-bound uPA, and uPA bound to its cell surface receptor. The assay detects active uPA and its inactive proenzyme form, pro-uPA, equally well. The limit of detection is approximately 1 pg of pro-uPA in a volume of 100 microliters, and there is a linear dose-response up to 100 pg pro-uPA. The efficiency in extracting uPA of a neutral non-detergent buffer used to prepare cytosol extracts was compared with that of 4 other buffers. There was a pronounced difference in the efficiency, the most efficient being a pH 4.2 buffer containing the non-ionic detergent Triton X-100, while the least efficient was the buffer used to prepare cytosols. Nevertheless, uPA immunoreactivity was readily measurable in the cytosols, and there was a close correlation between the amounts of uPA extracted under optimal conditions and those routinely used for steroid hormone receptor analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

尿激酶型纤溶酶原激活剂(uPA)在癌症侵袭中起作用,据报道,乳腺癌组织去污剂提取物中高水平的uPA与预后不良有关。我们探讨了将常规用于类固醇受体分析的乳腺癌细胞溶质提取物用于uPA回顾性预后研究的可能性。开发了一种用于uPA的夹心酶联免疫吸附测定(ELISA),使用多克隆捕获抗体和三种生物素化单克隆检测抗体的混合物,这些抗体被选择用于识别游离uPA、抑制剂结合的uPA以及与其细胞表面受体结合的uPA。该测定法对活性uPA及其无活性的酶原形式——pro-uPA的检测效果相同。检测限约为100微升体积中1皮克的pro-uPA,在100皮克pro-uPA范围内存在线性剂量反应。将用于制备细胞溶质提取物的中性非去污剂缓冲液提取uPA的效率与其他4种缓冲液的效率进行了比较。效率存在显著差异,最有效的是含有非离子去污剂Triton X-100的pH 4.2缓冲液,而效率最低的是用于制备细胞溶质的缓冲液。然而,在细胞溶质中很容易测量到uPA免疫反应性,并且在最佳条件下提取的uPA量与常规用于类固醇激素受体分析的量之间存在密切相关性。(摘要截短为250字)

相似文献

1
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.人乳腺癌组织胞质提取物中尿激酶型纤溶酶原激活剂(uPA)的酶联免疫吸附测定。
Breast Cancer Res Treat. 1993 Dec;28(3):223-9. doi: 10.1007/BF00666583.
2
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.乳腺癌组织提取物中的尿激酶受体。采用单克隆抗体和多克隆抗体组合的酶联免疫吸附测定。
Breast Cancer Res Treat. 1995 Mar;33(3):199-207. doi: 10.1007/BF00665944.
3
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.采用酶联免疫吸附测定法对乳腺癌提取物中尿激酶型纤溶酶原激活剂及其1型抑制剂之间的复合物进行定量分析。
J Immunol Methods. 1997 Apr 11;203(1):55-65. doi: 10.1016/s0022-1759(97)00008-2.
4
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.乳腺癌组织的胞质溶胶和去污剂提取物均适合评估尿激酶型纤溶酶原激活物及其抑制剂1型纤溶酶原激活物抑制剂的预后影响。
Cancer Res. 1994 May 15;54(10):2527-30.
5
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.尿激酶型纤溶酶原激活剂(uPA)及其抑制剂(PAI-1)对892例乳腺癌患者胞质溶胶和沉淀提取物的预后影响。
Br J Cancer. 1999 Mar;79(7-8):1190-8. doi: 10.1038/sj.bjc.6690191.
6
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.肺癌组织提取物中尿激酶型纤溶酶原激活剂与其受体复合物的酶联免疫吸附测定
Int J Cancer. 1997 Jul 29;72(3):416-23. doi: 10.1002/(sici)1097-0215(19970729)72:3<416::aid-ijc8>3.0.co;2-s.
7
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.尿激酶型纤溶酶原激活剂(uPA)的免疫测定(ELISA):欧洲癌症研究与治疗组织/生物医学1研讨会报告
Eur J Cancer. 1996 Jul;32A(8):1371-81. doi: 10.1016/0959-8049(96)00118-9.
8
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.乳腺癌细胞溶质提取物中高水平的尿激酶型纤溶酶原激活剂及其抑制剂PAI-1与预后不良相关。
Cancer Res. 1993 Jun 1;53(11):2513-21.
9
Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue.
Eur J Cancer. 2003 May;39(7):899-908. doi: 10.1016/s0959-8049(03)00025-x.
10
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.胞质肿瘤提取物中的1型纤溶酶原激活物抑制剂可预测低风险乳腺癌患者的预后。
Clin Cancer Res. 1997 Feb;3(2):233-9.

引用本文的文献

1
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines.nm23与乳腺癌组织及细胞系中蛋白水解因子、增殖和迁移的关系。
Br J Cancer. 1998 Sep;78(6):710-7. doi: 10.1038/bjc.1998.566.
2
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.三种人乳腺癌细胞系中的尿激酶型纤溶酶原激活与其体外侵袭性相关。
Clin Exp Metastasis. 1996 May;14(3):297-307. doi: 10.1007/BF00053903.
3
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.

本文引用的文献

1
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.尿激酶受体存在于乳腺导管癌的肿瘤相关巨噬细胞中。
Cancer Res. 1993 Apr 15;53(8):1911-5.
2
Cellular receptor for urokinase-type plasminogen activator: protein structure.尿激酶型纤溶酶原激活剂的细胞受体:蛋白质结构
Methods Enzymol. 1993;223:207-22. doi: 10.1016/0076-6879(93)23047-q.
3
Improved medium for extraction of plasminogen activator from tissue.用于从组织中提取纤溶酶原激活剂的改良培养基。
乳腺癌组织提取物中的尿激酶受体。采用单克隆抗体和多克隆抗体组合的酶联免疫吸附测定。
Breast Cancer Res Treat. 1995 Mar;33(3):199-207. doi: 10.1007/BF00665944.
Prep Biochem. 1982;12(4):297-305. doi: 10.1080/00327488208065678.
4
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.通过单克隆抗体亲和层析从人胶质母细胞瘤细胞中纯化酶原至纤溶酶原激活剂。
Biochemistry. 1982 Dec 7;21(25):6410-5. doi: 10.1021/bi00268a014.
5
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.特异性抑制一种人类52,000道尔顿纤溶酶原激活酶的单克隆抗体。
Proc Natl Acad Sci U S A. 1982 Jun;79(12):3720-3. doi: 10.1073/pnas.79.12.3720.
6
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.尿激酶型纤溶酶原激活物在Lewis肺癌中的免疫细胞化学定位
J Cell Biol. 1984 Aug;99(2):753-7. doi: 10.1083/jcb.99.2.753.
7
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.来自纤维肉瘤细胞的针对人54000分子量纤溶酶原激活物抑制剂的单克隆抗体——抑制剂中和及一步亲和纯化
Thromb Haemost. 1986 Apr 30;55(2):206-12.
8
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.尿激酶型纤溶酶原激活剂,侵袭性乳腺癌的一个标志物。初步报告。
Cancer. 1988 Aug 1;62(3):531-3. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b.
9
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.尿激酶型纤溶酶原激活剂的灵敏且特异的酶联免疫吸附测定法及其在乳腺癌患者血浆中的应用。
J Lab Clin Med. 1988 Jan;111(1):42-51.
10
Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin.尿激酶型和组织型纤溶酶原激活剂在银屑病皮肤中的免疫组化定位
J Invest Dermatol. 1987 Jan;88(1):28-32. doi: 10.1111/1523-1747.ep12464827.